» Articles » PMID: 28444290

Low-density Lipoproteins Cause Atherosclerotic Cardiovascular Disease. 1. Evidence from Genetic, Epidemiologic, and Clinical Studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel

Abstract

Aims: To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD).

Methods And Results: We assessed whether the association between LDL and ASCVD fulfils the criteria for causality by evaluating the totality of evidence from genetic studies, prospective epidemiologic cohort studies, Mendelian randomization studies, and randomized trials of LDL-lowering therapies. In clinical studies, plasma LDL burden is usually estimated by determination of plasma LDL cholesterol level (LDL-C). Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD. Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent dose-dependent log-linear association between the absolute magnitude of exposure of the vasculature to LDL-C and the risk of ASCVD; and this effect appears to increase with increasing duration of exposure to LDL-C. Both the naturally randomized genetic studies and the randomized intervention trials consistently demonstrate that any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C, provided that the achieved reduction in LDL-C is concordant with the reduction in LDL particle number and that there are no competing deleterious off-target effects.

Conclusion: Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.

Citing Articles

Early prediction of postpartum dyslipidemia in gestational diabetes using machine learning models.

Jiang Z, Chen X, Lai Y, Liu J, Ye X, Chen P Sci Rep. 2025; 15(1):8028.

PMID: 40055456 PMC: 11889255. DOI: 10.1038/s41598-025-92299-9.


Mitochondria-associated endoplasmic reticulum membranes and myocardial ischemia: from molecular mechanisms to therapeutic strategies.

Chen C, Dai G, Fan M, Wang X, Niu K, Gao W J Transl Med. 2025; 23(1):277.

PMID: 40050915 PMC: 11884070. DOI: 10.1186/s12967-025-06262-3.


Associations of patient knowledge with drug-modifiable cardiovascular risk factor control in coronary artery disease patients with and without diabetes mellitus: results from the cross-sectional KNOW-ABC study.

Brockmeyer M, Fell M, Parco C, Hoss A, Vargas K, Wies E BMC Cardiovasc Disord. 2025; 25(1):148.

PMID: 40045198 PMC: 11881313. DOI: 10.1186/s12872-025-04599-7.


Association between small dense low-density lipoprotein and carotid intima-media thickness.

Khosravi M, Sheikhnia F, Pashaei M, Karimi-Dehkordi M, Alizadeh-Fanalou S J Cardiovasc Thorac Res. 2025; 16(4):202-210.

PMID: 40027367 PMC: 11866774. DOI: 10.34172/jcvtr.33145.


Targeting Lysophosphatidic Acid Ameliorates Dyslipidemia in Familial Hypercholesterolemia.

Du Z, Wang Y, Li F, Sun X, Du Y, Li L Research (Wash D C). 2025; 8:0629.

PMID: 40018730 PMC: 11865365. DOI: 10.34133/research.0629.


References
1.
Khera A, Won H, Peloso G, Lawson K, Bartz T, Deng X . Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol. 2016; 67(22):2578-89. PMC: 5405769. DOI: 10.1016/j.jacc.2016.03.520. View

2.
Wiegman A, Gidding S, Watts G, Chapman M, Ginsberg H, Cuchel M . Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015; 36(36):2425-37. PMC: 4576143. DOI: 10.1093/eurheartj/ehv157. View

3.
Camejo G, Lopez A, Vegas H, Paoli H . The participation of aortic proteins in the formation of complexes between low density lipoproteins and intima-media extracts. Atherosclerosis. 1975; 21(1):77-91. DOI: 10.1016/0021-9150(75)90095-7. View

4.
Ference B, Robinson J, Brook R, Catapano A, Chapman M, Neff D . Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J Med. 2016; 375(22):2144-2153. DOI: 10.1056/NEJMoa1604304. View

5.
Garcia-Calvo M, Lisnock J, Bull H, Hawes B, Burnett D, Braun M . The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005; 102(23):8132-7. PMC: 1149415. DOI: 10.1073/pnas.0500269102. View